Image: ARND WIEGMANN (REUTERS)
Initially, 3.2 billion US dollars would be paid, Novartis announced on Monday. With the acquisition, Novartis is primarily strengthening its pipeline in the field of kidney diseases, as Chinook is developing two late-stage compounds in this area.
The acquisition includes a cash payment of over $40 per Chinook share and a possible future cash bonus of up to $4 per share upon achievement of certain development results. Novartis expects to close the transaction in the second half of 2023.
more from economy
